Company Profile
Allogene Therapeutics Stock Price, News & Analysis
- Ticker:
- ALLO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.97 USD (+1.03%)
Close
Last updated: August 6, 2026
708M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ALLO closed up 1.03% at $1.97. No new same-company headline was identified in the current news window.
Company overview
Allogeneic CAR T Company
Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease.
Cema-cel
Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for rapid administration without patient-specific manufacturing.
First-Line LBCL Strategy
The pivotal Phase 2 ALPHA3 study evaluates cema-cel as outpatient consolidation therapy for first-line large B-cell lymphoma patients who remain minimal residual disease-positive after standard treatment.
Platform Optimization
Allogene is optimizing lymphodepletion, dosing, and manufacturing to improve expansion, persistence, safety, and treatment access.
Future catalysts
The next clinical update from ongoing dose-escalation and lymphodepletion optimization is expected in the fourth quarter of 2026.
Recent news
- 01
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Source: Allogene Therapeutics
- 02
- 03
- 04
Allogene Therapeutics Announces Planned CEO Succession
Source: Allogene Therapeutics
- 05
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Source: Allogene Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Allogene Therapeutics (ALLO)?
Allogene Therapeutics (ALLO) most recently closed at 1.97 USD, a +1.03% move versus the previous session.
What is the market cap of Allogene Therapeutics (ALLO)?
Allogene Therapeutics currently has a market capitalization of 708M USD on BioPharmSignal.
What does Allogene Therapeutics do?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Cema-cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for rapid administration without patient-specific manufacturing. First-Line LBCL Strategy The pivotal Phase 2 ALPHA3 study evaluates...
On which exchange is ALLO stock listed?
Allogene Therapeutics (ALLO) is associated with NASDAQ, United States, Biopharma.
What is Allogeneic?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease.
Which conditions is Allogene Therapeutics targeting with Allogeneic?
Allogene Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Allogene Therapeutics describe recent progress with Allogeneic?
The next clinical update from ongoing dose-escalation and lymphodepletion optimization is expected in the fourth quarter of 2026.
What is Allogene?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease.